Dr. Kelly is a gastroenterologist at Brigham and Women’s Hospital, faculty member at Harvard Medical School, and Chief Medical Adviser to OpenBiome Foundation. A national leader in Clostridioides difficile infection and fecal microbiota transplantation (FMT), she led the first placebo-controlled FMT trial for recurrent CDI and sponsored one of the earliest FDA INDs for FMT, shaping regulatory guidance for microbiota-based therapies. She is principal investigator of the National Institutes of Health–funded FMT National Patient Registry and has authored major clinical guidelines, including the American College of Gastroenterology 2021 CDI guidelines and the American Gastroenterological Association guideline on fecal microbiota-based therapies. Dr. Kelly also serves on the Clinical Advisory Board.